P/B
22,7
Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
$14.3B
Market Cap • 10/7/2026
2020
(6 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
16,4
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,8
EPS
—
Market Cap
Market Cap
14,3B
EV
13,6B
EV/Revenue
0
EV/EBITDA
15,6
EV/EBIT
15,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-5,9%
Total Yield
-5,9%
Payout
0%
Retained Earnings
-2,7B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
798,3%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
2,6%
% Goodwill
0,3%
ROE
—
ROIC
3296,8%
Growth
CAGR Net Income 5Y
55%
CAGR EPS 5Y
4%
CAGR OCF 5Y
42%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
7
Quick Ratio
6,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!